Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors.
Bioorg Med Chem Lett
; 18(18): 5095-100, 2008 Sep 15.
Article
em En
| MEDLINE
| ID: mdl-18722116
ABSTRACT
Starting from the previously reported HCV NS3/4A protease inhibitor BILN 2061, we have used a fast-follower approach to identify a novel series of HCV NS3/4A protease inhibitors in which (i) the P3 amino moiety and its capping group have been truncated, (ii) a sulfonamide is introduced in the P1 cyclopropyl amino acid, (iii) the position 8 of the quinoline is substituted with a methyl or halo group, and (iv) the ring size of the macrocycle has been reduced to 14 atoms. SAR analysis performed with a limited set of compounds led to the identification of N-{17-[8-chloro-2-(4-isopropylthiazol-2-yl)-7-methoxyquinolin-4-yloxy]-2,14-dioxo-3,15-diazatricyclo [13.3.0.0 [Bartenschlager, R.; Lohmann, V. J. Gen. Virol. 2000, 81, 1631; Vincent Soriano, Antonio Madejon, Eugenia Vispo, Pablo Labarga, Javier Garcia-Samaniego, Luz Martin-Carbonero, Julie Sheldon, Marcelle Bottecchia, Paula Tuma, Pablo Barreiro Expert Opin. Emerg. Drugs, 2008, 13, 1-19]]octadec-7-ene-4-carbonyl}(1-methylcyclopropyl)(1-methylcyclopropyl)sulfonamide 19l an extremely potent (K(i)=0.20 nM, EC(50)=3.7 nM), selective, and orally bioavailable dipeptide NS3/4A protease inhibitor, which has features attractive for further preclinical development.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Quinolinas
/
Sulfonamidas
/
Tiazóis
/
Carbamatos
/
Inibidores de Serina Proteinase
/
Proteínas não Estruturais Virais
/
Compostos Macrocíclicos
Idioma:
En
Ano de publicação:
2008
Tipo de documento:
Article